Modus Therapeutics resolves directed share issue at SEK 0.38
Modus Therapeutics’ board resolved a directed new issue of 20,000,000 shares at a subscription price of SEK 0.38, pursuant to AGM authorisation from 28 May 2026.
The Board of Directors of Modus Therapeutics Holding AB (“Modus Therapeutics” or the “Company”) has today, pursuant to the authorisation granted by the annual general meeting held on 28 May 2026, resolved to carry out a directed new issue of 20,000,000 shares at a subscription price of SEK 0.38 per…